Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oseltamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL455879 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL18117995 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL8730 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL29085770 | 1.00 | MEN1 (0.81) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28613342 | 0.99 | MEN1 (0.80) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28299940 | 0.96 | MEN1 (0.75) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL4234896 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 0.96 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051897-A1 | SYNTHESIS OF COMPLEX 15N-LABELED MOLECULES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-02-15 | — | — | US | disclosed |
| US-9040738-B2 | Intermediate compounds of tamiflu, methods of preparation and uses thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051897-A1 | SYNTHESIS OF COMPLEX 15N-LABELED MOLECULES | NCLN, NCL, NDUFV3 | MEN1 425/4885LMNA 1483/4885CYP3A4 865/4885 |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | NNMT, FLT3, TPMT | MEN1 2258/4885LMNA 1845/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.